## ADMA: ADMA Biologics Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.40 fails VALUE criteria (<1.0); RSI 73 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.9% MRS), overbought RSI (73).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump**
- Source: Simply Wall Street | 20251203T051007 | Somewhat-Bullish | Relevance: 99%
-  ADMA Biologics (NASDAQ:ADMA) has experienced a 25% price jump recently, though its share price is still down 2.7% over the last twelve months. The company's P/E ratio of 22x is higher than the market average of 18x, which is attributed to its impressive earnings growth of 198% in the last year and a projected 21% annual EPS increase over the next three years. This strong growth outlook makes shareholders comfortable with the elevated P/E ratio.

**2. ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump**
- Source: Sahm | 20251203T051007 | Somewhat-Bullish | Relevance: 97%
-  ADMA Biologics (NASDAQ:ADMA) has experienced a 25% price jump in the last month, but its shares are still down 2.7% over the past year. The company's P/E ratio of 22x is higher than the U.S. market average, but this is attributed to its impressive earnings growth of 198% last year and anticipated EPS climb of 21% annually over the next three years, significantly outperforming the market forecast of 11%. Despite past mixed results, analysts are optimistic about its future growth, justifying the higher P/E.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.08M) |
| Sells | 2 ($0.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Elevated short interest (9.6%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.40 suggests fair value with growth premium. Forward P/E 20.7x attractive for 61% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.43 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.40 |
| Forward P/E | 20.7 |
| Current P/E | 33.4 |
| YoY Growth | 61.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 8.0% to 2.1% (-5.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Outperforming sector by 4.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.11% (CS: 73) | Neutral |
| RSI_14 | 73.2 | Overbought |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.142x | Above |
| vs SMA50 | 1.250x | Above |
| vs SMA200 | 1.104x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.85
- **Stop Loss:** $18.35 (7.6% risk)
- **Target:** $21.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 333
- **Position Value:** $6,610.05
- **Portfolio %:** 6.61%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*